摘要
目的探讨罗沙司他治疗肾性贫血的效果及其对睡眠质量和疲乏状态的影响。方法选取2022年1月至4月潍坊医学院附属医院、潍坊峡山医院、潍坊市益都中心医院、昌乐齐城中医院四个透析中心共收治的625例符合肾性贫血诊断的血液透析患者作为研究对象,根据抽签法将其分为两组,罗沙司他组278例,促红细胞生成素(EPO)组347例。罗沙司他组给予罗沙司他治疗;EPO组给予促红细胞生成素和蔗糖铁治疗。比较两组患者治疗3个月后临床指标、认知功能、睡眠质量、疲乏程度及生活质量等量表评分情况。结果治疗前,两组患者血红蛋白(HGB)、铁蛋白、白蛋白(ALB)、C反应蛋白(CRP)和平均动脉压(MAP)比较,差异无统计学意义(P>0.05);治疗后,两组患者的HGB、铁蛋白、ALB均高于本组治疗前,MAP低于本组治疗前,且罗沙司他组患者的HGB、ALB均高于EPO组,铁蛋白、MAP均低于EPO组,罗沙司他组患者CRP低于本组治疗前及EPO组,差异有统计学意义(P<0.05)。治疗前,两组患者蒙特利尔认知评估量表(MoCA)评分、匹兹堡睡眠质量指数(PSQI)评分、生活质量量表(SF-36)评分、疲劳评定量表(FAI),差异无统计学意义(P>0.05);治疗后,两组患者的MoCA评分、SF-36评分高于本组治疗前,PSQI评分、FAI评分低于本组治疗前,且罗沙司他组SF-36评分高于EPO组,PSQI评分、FAI评分低于EPO组,差异有统计学意义(P<0.05)。结论罗沙司他可有效改善肾性贫血,减轻患者疲乏状态、改善睡眠质量。
Objective To investigate the effect of Roxadustat on renal anemia and its influence on sleep quality and fatigue.Methods A total of 625 hemodialysis patients who met the diagnosis of renal anemia admitted to four dialysis centers of Affiliated Hospital of Weifang Medical University,Weifang Xiashan Hospital,Weifang Yidu Central Hospital and Changle Qicheng Traditional Chinese Medicine Hospital from January to April 2022 were selected as the research objects.According to the drawing lots method,they were divided into two groups,with 278 cases in Roxadustat group,and 347 cases in erythropoietin(EPO)group.The Roxadustat group was treated with Roxadustat.The EPO group was treated with erythropoietin and iron sucrose.The scores of clinical indicators,cognitive function,sleep quality,fatigue and quality of life were compared between the two groups after 3 months of treatment.Results Before treatment,there were no statistically significant differences in hemoglobin(HGB),ferritin,albumin(ALB),C-reactive protein(CRP)and mean arterial pressure(MAP)between the two groups(P>0.05).After treatment,the HGB,ferritin and ALB of the two groups were higher than those before treatment,and the MAP was lower than that before treatment,and the HGB and ALB of the Roxadustat group were higher than those of the EPO group,the ferritin and MAP were lower than those of the EPO group,and the CRP of the Roxadustat group was lower than that before treatment and the EPO group,and the differences were statistically significant(P<0.05).Before treatment,there were no statistically significant differences in Montreal cognitive assessment(MoCA)score,Pittsburgh sleep quality index(PSQI)score,quality of life questionnaire(SF-36)score and fatigue assessment scale(FAI)score between the two groups(P>0.05).After treatment,MoCA score and SF-36 score of the two groups were higher than those before treatment,PSQI score and FAI score were lower than those before treatment,and SF-36 score of Roxadustat group was higher than that of EPO group,PSQI score and FAI score was lower than that of EPO group,the differences were statistically significant(P<0.05).Conclusion Roxadustat can effectively improve renal anemia,reduce fatigue and improve sleep quality of patients.
作者
徐慧颖
赵袆
袁梦雪
张海波
耿怀营
柴春香
陈学勋
李璇
XU Huiying;ZHAO Hui;YUAN Mengxue;ZHANG Haibo;GENG Huaiying;CHAI Chunxiang;CHEN Xuexun;LI Xuan(Department of Nephrology,Affiliated Hospital of Weifang Medical University,Shandong Province,Weifang 261041,China;Department of Nephrology,Weifang Yidu Central Hospital,Shandong Province,Qingzhou 262500,China;Department of Nephrology,Weifang Xiashan Hospital,Shandong Province,Weifang 261000,China;Department of Nephrology,Changle Qicheng Hospital of Traditional Chinese Medicine,Shandong Province,Changle 262400,China)
出处
《中国当代医药》
CAS
2023年第22期11-14,42,共5页
China Modern Medicine
基金
山东省潍坊市软科学研究计划项目(2021RKX047、2019RKX132、2021RKX018、2019RKX088)。
作者简介
通讯作者:李璇。
